Malaysia and Singapore medical devices markets: size, growth and outlook 2026–2032

Southeast Asia's device manufacturing and regulatory hubs — key sources for GCC tenders. Published estimates normalised to 2025 range from — to —; the Consulting Wallah central estimate is USD 4.9 bn, growing at about 8% a year to USD 8.4 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by malaysia: NIMP 2030 push to higher-value devices; exports RM 34.54 bn (2025) with >RM 50 bn target by 2030; malaysia: MoH budget +13.2% (2024), +10% (2025); 10 of world's top device companies manufacture locally; singapore: >SGD 20 bn medtech output, world's top 30 medtech companies present, >3,000 precision-engineering suppliers.

Context that matters for buyers and suppliers: Malaysia medical device exports reached RM 34.54 bn in 2025; government targets >RM 50 bn by 2030. Malaysia sources ~95% of domestic device demand from abroad; top-5 suppliers (Greater China, Singapore, US, Germany, Japan) >68%. Ten of the world's top medical device companies have manufacturing operations in Malaysia (incl. Abbott, B. Braun, Boston Scientific, Teleflex). Singapore medtech manufacturing output > SGD 20 bn employing >17,000; world's top 30 medtech companies present.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is —–—; differences are mostly scope.

Included: capital equipment, implants, single-use consumables and IVD instruments and reagents. Excluded: pharmaceuticals, hospital IT, commodity PPE where reported separately. Publishers differ on whether IVD and consumables are included.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Malaysia medical device exports reached RM 34.54 bn in 2025; government targets >RM 50 bn by 2030 (Malay Mail)
• Malaysia sources ~95% of domestic device demand from abroad; top-5 suppliers (Greater China, Singapore, US, Germany, Japan) >68% (Pure Global)
• Ten of the world's top medical device companies have manufacturing operations in Malaysia (incl. Abbott, B. Braun, Boston Scientific, Teleflex) (MIDA)
• Singapore medtech manufacturing output > SGD 20 bn employing >17,000; world's top 30 medtech companies present (Singapore EDB)
• Singapore: >80% of local demand imported, ~70% of imports re-exported; US products hold 24% of equipment market (US ITA)
• Singapore MoH accounts for ~75% of local device demand; public sector holds 80% of beds (US ITA)
• HSA regulates under Health Products Act; Class A non-sterile exempt from registration; GHTF-based classification (US ITA)
• HSA has device reliance programmes with Australia, Hong Kong, Malaysia, Philippines, Sri Lanka and Thailand (Singapore EDB)

Where the GCC and India sit

• Malaysia medical device exports: RM 34.54 bn (2025) — Malay Mail (DPM)
• Malaysia medical devices market: USD 4.5 bn by 2028 (2028) — MIDA / Pure Global
• Southeast Asia medical devices market: USD 15.8 bn by 2028 (2028) — MIDA
• Singapore medtech manufacturing output: > SGD 20 bn; >17,000 employed (2026) — Singapore EDB
• Singapore national health expenditure: USD 43-44 bn by 2030 (9.0% of GDP, up from 5.9%) (2030) — US ITA
• Asia-Pacific medtech demand: USD 132 bn by 2030 (2030) — Singapore EDB

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: contract manufacturing and high-end consumables (gloves, catheters), diagnostic imaging and point-of-care devices (MIDA investment priorities); singapore as regional HQ, re-export hub (~70% of imports re-exported) and HSA reliance programmes with 6 countries; malaysia target of 10 regional/global MedTech champions by 2030.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers and exporters: registration first, local partner second, tender readiness third — see what GCC buyers need.
• Hospital leaders: total cost of ownership (service, consumables, software) outweighs purchase price; tender the bundle.
• Investors: local assembly and distribution platforms backed by procurement preference.

1. MIDA, Medical Technology - Medical Devices industry page — mida.gov.my
2. Malay Mail, Malaysia aims to push medical device exports beyond RM50b by 2030 — malaymail.com
3. Pure Global, Research Report: Malaysia's Medical Device and IVD Market — pureglobal.com
4. US International Trade Administration, Singapore Country Commercial Guide - Healthcare — trade.gov
5. Singapore EDB, Singapore helps MedTech companies develop, manufacture and scale globally — edb.gov.sg
6. MedDeviceGuide, Singapore HSA Medical Device Registration Guide — meddeviceguide.com
7. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
8. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.